PCSK9 and neoplasm: PS significantly reduced PCSK9 expression level in vitro and in collected type II ADI CRPC tumors, suggesting possible dual extracellular and intracellular pathway of action, unlike the current humanized FDA-approved mAbs, which only act extracellularly since their large molecular size precludes tumor cells entry.